Introduction: Even in after curative surgery and adequate linfoadenectomy the survival of advanced gastric cancer (AGC) remains poor. At present some data have been published on the effects of NACT and perioperative chemotherapy on AGC and Esophago-gastric cancer (EGC) but not definitive ones. The present meta-analysis aims to evaluate the effects of neoadjuvant chemotherapy (NACT) on the AGC and EGC.
Material And Methods: A systematic review with meta-analysis of randomized controlled trials (RCTs) of NACT + surgery vs. Surgery in patients with AGC and EGC was performed.
Results: 15 RCTs have been included (2001 patients: 977 into NACT + surgery arm and 1024 into control arm). NACT + Surgery reduces the overall mortality at 1, 3 and 5-year in cumulative analysis (RR = 0.78; 0.81; 0.88 respectively), at 1, 2, 3 and 5-years in EGC (RR = 0.79; 0.83; 0.84; 0.91 respectively) and at 3 and 5-years in AGC (RR = 0.74; 0.82 respectively). Morbidity and perioperative mortality rate are not influenced by NACT. Recurrence rate is reduced by NACT + surgery in EGC (RR = 0.80).
Conclusions: NACT reduces the mortality in gastric and esophago-gastric cancer. Morbidity and perioperative mortality are not influenced by NACT. The overall recurrence rate is reduced by NACT in esophago-gastric cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijsu.2018.01.008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of sarcopenic obesity on postoperative outcomes in patients with oesophago-gastric cancer: A systematic review and meta-analysis.
World J Surg
December 2024
Department of Gastroenterological Surgery, Cancer Institute Ariake Hospital, Tokyo, Japan.
Background: We elucidated the influence of sarcopenic obesity on postoperative outcomes in patients with oesophago-gastric cancer.
Methods: We conducted a systematic search on MEDLINE, the Cochrane Central Register of Controlled Trials, EMBASE, the World Health Organization International Clinical Trials Platform Search Portal, and ClinicalTrials.gov to identify observational studies published from their inception to September 26, 2024.
Pre-Surgical Endoscopic Biopsies Are Representative of Esophageal and Esophago-Gastric Junction Adenocarcinoma Histologic Classes and Survival Risk.
Cancers (Basel)
December 2024
Pathology Unit, Department of Surgical Sciences and Integrated Diagnostics (DISC), University of Genoa, 16132 Genoa, Italy.
The Esophageal Adenocarcinoma Study Group Europe (EACSGE) recently proposed a granular histologic classification of esophageal-esophago-gastric junctional adenocarcinomas (EA-EGJAs) based on the study of naïve surgically resected specimens that, when combined with the pTNM stage, is an efficient indicator of prognosis, molecular events, and response to treatment. In this study, we compared histologic classes of endoscopic biopsies taken before surgical resection with those of the surgical specimen, to evaluate the potential of the EACSGE classification at the initial diagnostic workup. A total of 106 EA-EGJA cases with available endoscopic biopsies and matched surgical resection specimens were retrieved from five Italian institutions.
View Article and Find Full Text PDFExpression of therapy target molecules in esophagogastric junction and Barrett's adenocarcinoma.
Gastric Cancer
December 2024
Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Article Synopsis
- This study investigates the presence of therapeutic target molecules in esophagogastric junction (EGJ) and Barrett's adenocarcinomas, focusing on 114 non-Barrett's and 30 Barrett's cases.
- Various molecular markers were assessed, revealing that a majority of EGJ (81.6%) and Barrett's (86.7%) adenocarcinomas expressed at least one target molecule, with PD-L1 having a significant correlation with better survival rates.
- The findings suggest that most patients with EGJ and Barrett's adenocarcinoma could benefit from molecular targeted therapy, highlighting the importance of tailored treatments based on individual molecular profiles for improved outcomes.
REsolution of Symptoms afTer Oesophago-gastric cancer REsection delphi (RESTOREd)-standardizing the definition, investigation and management of gastrointestinal symptoms and conditions after surgery.
Br J Surg
November 2024
Department of Gastroenterology, United Lincolnshire Hospitals NHS Trust, Lincoln, UK.
Background: Oesophago-gastric cancer surgery negatively affects quality of life with a high postoperative symptom burden. Several conditions that may be diagnosed and treated after surgery are recognised. However, consensus regarding their definition and management is lacking.
View Article and Find Full Text PDFA national survey of the provision of prehabilitation for oesophagogastric cancer patients in the UK.
Ann R Coll Surg Engl
November 2024
Guy's and St Thomas' NHS Foundation Trust, UK.
Introduction: Studies have demonstrated that prehabilitation in oesophagogastric cancer (OGC) improves body composition, physical fitness and quality of life, and can reduce surgical complications. However, it is not offered in all OGC centres. Furthermore, definitions, funding and access to services vary.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!